HAL (France)open access
Glycemic and renal effects of SGLT2 Inhibitors in Prader-Willi syndrome: Benefits and risks
0, Prader willi syndrom, Type 2 diabetes, SGLT2 inhibitor
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 268648
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.